Skip to main content

Market Overview

Bristol Myers To Build First Cell Therapy Factory In Europe

Bristol Myers To Build First Cell Therapy Factory In Europe
  • Bristol-Myers Squibb Co (NYSE: BMY) continues to scale its CAR-T operations with the latest move to open its first cell manufacturing site in Europe and fifth worldwide.
  • BMY is set to build a new cell therapy site in Leiden, the Netherlands. Financial terms were not disclosed.
  • The site design planning and development are underway, with construction expected to kick off later this year.
  • The company's swift cell therapy scale-up follows the FDA green lights for its closely-watched CAR-T therapies Breyanzi and Abecma.
  • Abecma (idecabtagene vicleucel; ide-cel), approved in March, is a BCMA-directed chimeric antigen receptor (CAR) T cell immunotherapy to treat relapsed or refractory multiple myeloma.
  • Breyanzi (lisocabtagene maraleucel; liso-cel) was approved in February. It is a CD19-directed CAR-T cell therapy for relapsed or refractory large B-cell lymphoma.
  • None of these treatments are approved in Europe.
  • Price Action: BMY shares are down 0.09% at $66.26 in premarket on the last check Thursday.

Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: Briefs cell therapyBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at